![](https://library.celltelligence.com/wp-content/uploads/2023/12/Screenshot-2023-12-14-at-16.33.06.png)
$0
A New Pivotal Trial for Caribou’s CB-010 in ≥2L LBCL to Start in 2024; Is the FDA Changing Perspective on the Clinical Development of Allogeneic CAR-Ts in Earlier Lines?
On Tuesday, December 12, Caribou announced (press release) positive FDA feedback for the initiation of a Ph3 trial evaluating CB-010 (allogeneic CD19 CAR-T; PD-1 KO + TCR KO) in patients with ≥2L LBCL, set to start by YE 2024. Below, Celltelligence provides insights on the significance of the FDA’s decision, discussing the possible outcomes of CB-010 in ≥2L LBCL and the hurdles that Caribou could encounter along the clinical development of its lead asset.